1. Introduction {#s0005}
===============

Cancer is an aberrant, uncontrolled growth of cells caused by myriad damage or mutations in the genetic material of the cells due to hereditary or environmental factors, which become immune to many signals controlling cellular growth and death often having the potentiality of invading or spreading to varied body parts ([@bb0005]). DNA double strand breaks (DSBs) are the most injurious among different types of DNA lesions caused by exogenous toxins such as environmental mutagens and chemical carcinogens in conjunction with endogenous sources resulting from reactive oxygen species (ROS) assembly during cellular respiration etc. ([@bb0010; @bb0015]). It has been proposed that a single unrepaired DSB might be enough to evoke cell death ([@bb0020]) whereas misrepaired DSBs can result in loss of genetic information, harmful mutation and chromosomal rearrangements which can lead to cancer development ([@bb0025]).

One of the frequently mutated genes in cancer that functions upstream of *TP53* in the DNA damage response (DDR) pathway and conceivably linked to the escape from apoptosis/senescence hallmark is the ataxia-telangiectasia mutated (*ATM*) located on the long arm of chromosome 11 (11q22--23) and covers around 160 Kb of genomic DNA ([@bb0015; @bb0030]). The ATM protein is a large 370 kDa serine/threonine kinase that activates over a hundred proteins involved in DDR and other cellular responses like DSB repair, cell cycle regulation, chromatin remodeling, apoptosis etc. and its loss of function contributes to the major features of rare neurodegenerative autosomal recessive disorder ataxia-telangiectasia (AT) including increased cancer risk ([@bb0010; @bb0025; @bb0035]).

The *ATM* gene has 66 exons and the first four exons lie in the 5′-UTR which undergo extensive alternative splicing thereby giving rise to different mRNA transcripts with varying sequences and lengths having different regulatory roles via the formation of different secondary structures and varying number of start codons ([@bb0015; @bb0040]). Of the majority of the *ATM* single nucleotide polymorphisms (SNPs), the rs189037 (G \> A), located at the 5\'UTR of the promoter region of *ATM* gene is one of the vital SNPs associated with the risk of several cancers.

Epidemiological studies around the globe confirmed the association between various *ATM* polymorphisms in different cancer risks ([@bb0045; @bb0050; @bb0055; @bb0060; @bb0065; @bb0070]).Various articles related to rs189037 SNP in promoter region of the *ATM* gene and the risk of different cancers have also been published ([@bb0075; @bb0080; @bb0085; @bb0090; @bb0095; @bb0100; @bb0105; @bb0110; @bb0115]). However, the results were not conclusive. In order to evaluate the association between rs 189037 SNP and cancer risk, we have performed a meta-analysis from relevant scientific literatures.

2. Materials and methods {#s0010}
========================

2.1. Identification and eligibility of relevant literatures {#s0015}
-----------------------------------------------------------

A range of electronic databases (PubMed, Google Scholar, SNPedia, OMIM, Cochrane library) were searched (last search update was 2015 March) using the search terms 'ATM', 'polymorphism', 'cancer', and 'rs189037 in *ATM*'. Manual search of references identified in relevant publication was also performed to find other relevant literatures.

Studies included in our meta-analysis followed the inclusion criteria mentioned below: (1) All were case--control studies related to rs189037 (G \> A) polymorphism, (2) Control group were in accordance with Hardy--Weinberg equilibrium, (3) Details of genotype frequencies of *ATM* rs189037G \> A genetic polymorphisms, and (4) Only studies in English literature were considered for this meta-analysis. The major exclusion criteria: (1) No control group, and (2) No details of genotype frequencies of desired polymorphism.

2.2. Data extraction & quality assessment {#s0020}
-----------------------------------------

Data were carefully extracted from all eligible publications independently by two of the authors, according to the inclusion criteria mentioned above. The data were collected from each relevant study according to the following details: the first author\'s full name, publication year, ethnicity of studied population, design of study, genotyping methods, genotype frequencies etc. The critical appraisal skills program (CASP) for case--control studies (<http://www.casp-uk.net>/) was performed for quality assurance of the selected eligible studies considered for the quantitative analysis. The scoring pattern for the CASP criteria is as follows: the study addresses a clearly focused issue (CASP1); an appropriate research design answers the research problem (CASP2); the selected cases were inscribed acceptably (CASP3); the controls were selected acceptably (CASP4); the measurement for exposure factors is precise to minimize classification bias (CASP5); the potential confounding factors are considered in the study design/analysis (CASP6); the research results are accomplished (CASP7); the research results are accurate (CASP8); the research results are authentic (CASP9); the research results are applicable to the local population (CASP10); and the research results fit with other available evidence like systematic reviews, case--control studies, cohort studies etc. (CASP11).

2.3. Statistical analysis {#s0025}
-------------------------

Meta-analysis was performed using the StatsDirect Statistical software (version 2.7.2). The intensity of the association between SNP and cancers was calculated from odds ratios (ORs) with 95% confidence intervals (CIs). The Z test was performed to estimate the statistical significance of pooled OR. Genotype frequencies of control group were tested for HWE using χ^2^ test. Cochran\'s Q statistic and I^2^ tests were used to test the heterogeneity between studies ([@bb0120]). If Q test shows a p \< 0.05 or I^2^ demonstrates \> 50% which indicates significant heterogeneity, the random effect model was chosen otherwise the fixed effects model was used. Sensitivity analysis was performed to check the potential outliers each time omitting a single study. Funnel plots and Egger\'s linear regression test were conducted to investigate the significant publication bias ([@bb0125]). In funnel plot standard error of log (OR) of each study was plotted against its log (OR) and an asymmetric plot suggested possible publication bias. On other hand the degree of asymmetry was tested using Egger\'s test where p \< 0.05 indicates significant publication bias. The pooled OR was considered to be significant at p \< 0.05.

3. Results {#s0030}
==========

3.1. Characteristics of studies {#s0035}
-------------------------------

Initially we identified total 42 studies from different database and manual searches. After reviewing the titles and abstracts, we excluded 4 studies. Out of 38 remaining studies, 29 were excluded further. Finally, 9 case--control studies containing of 4507 cancer patients and 4778 control subjects, met our inclusion criteria for quantitative data analysis ([Fig. 1](#f0005){ref-type="fig"}). Overall, the studies were carried out among 8 Asians and 1 Caucasian population according to the inclusion criteria. CASP scores and the characteristics of all the studies are summarized in [Fig. 2](#f0010){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}, respectively ([@bb0075; @bb0080; @bb0085; @bb0090; @bb0095; @bb0100; @bb0105; @bb0110; @bb0115]).

3.2. Meta-analysis result {#s0040}
-------------------------

The pooled ORs for *ATM* rs189037G \> A and cancer risk is listed in [Table 2](#t0010){ref-type="table"}. The homozygote model (GG vs. AA) showed significant heterogeneity (p = 0.01, I^2^ = 63.6%) and the random effects pooled OR was 1.23 (95% CI = 1.00--1.51) at p = 0.053. The dominant model (GG vs. GA + AA) showed no heterogeneity and the fixed effects pooled OR was found to be significant (OR = 1.14, 95% CI = 1.05--1.25) at p = 0.003. On other hand recessive model (GG + GA vs. AA) showed significant heterogeneity (p = 0.01, I^2^ = 60.7%) and the random effects pooled OR did not show any significant result (OR = 1.17, 95% CI = 1.00--1.40) (p = 0.068). The association between A allele and the risk of developing cancer relative to the allele G revealed significant heterogeneity (p = 0.01, I^2^ = 63.7%) but the random effects pooled OR did not show significant result (OR = 1.11, 95% CI = 1.00--1.23, p = 0.046). Homozygote wild and heterozygote alleles (GG vs. GA) showed no heterogeneity and the pooled OR for fixed effects was not significant (OR = 1.09, 95% CI = 1.00--1.20, p = 0.066). However, the pooled OR for fixed effects of heterozygote and homozygote mutant allele (GA vs. AA) model was significant (OR = 1.17, 95% CI = 1.04--1.30, p = 0.006) and no heterogeneity was observed for this model ([Fig. 3](#f0015){ref-type="fig"}).

Sensitivity test was assigned to check the influence of each studies on overall pooled OR. Begg--Mazumdar\'s funnel plot ([Fig. 4](#f0020){ref-type="fig"}) did not show any publication asymmetry which was confirmed by Egger\'s test. There was no publication bias for *ATM* rs189037G \> A (Homozygote model: tau = − 0.11, p = 0.24; Dominant model: tau = − 0.11, p = 0.33; Recessive model: tau = − 0.39, p = 0.26; Allele model: tau = − 0.06, p = 0.34; Homozygote wild type vs. Heterozygote model: tau = − 0.22, p = 0.39; Heterozygote vs. Homozygote mutant model: tau = − 0.39, p = 0.33).

4. Discussion {#s0045}
=============

ATM is one of the central kinases in cellular responses to DNA DSBs. ATM is recruited by the MRN complex (MRE11-RAD50-NBS1) to the site of DNA DSBs. The C-terminus of NBS1 acts as the binding site for ATM, thereby enhancing its kinase activity. Immediately after recruitment, ATM phosphorylates the histone variant H2AX on serine 139, which further recruits additional proteins in DNA damage response pathway and helps ATM to amplify its signal and form discrete ATM foci at DNA DSBs ([@bb0015]). In response to DNA damage, ATM also interacts with different downstream effectors and induces different signaling functions like cell cycle check point arrest with p53, Mdm2 and Chk2 at G1, damage induced S-phase arrest with NBS1, BRCA1, FancD2 and SMC1, G2/M arrest with BRCA1 and hRad17 and apoptosis with E2F1, Chk2, P53, P73 and Bax ([@bb0015]).

The polymorphism rs189037 is located at the 5′UTR of the promoter region of *ATM* gene ([@bb0130]). It was evident from different studies that polymorphisms in the promoter region of a gene may change the binding sites of transcription factors, which affects gene expression. The heterozygote of rs189037 has been observed to be significantly related to longevity through an effect on ATM transcript like AP-2α, a transcription factor that participates in many important life processes ([@bb0040; @bb0135; @bb0140]). There are other possibilities of one or more transcription factors which are regulated by rs189037, and thus different genotypes may up-regulate or down-regulate the expression of *ATM* gene, which may lead to cancer formation.

Different case--control studies have reported the association of rs189037 polymorphism and risk of different cancers ([@bb0075; @bb0080; @bb0085; @bb0090; @bb0095; @bb0100; @bb0105; @bb0110]). ([@bb0075]), ([@bb0085]) and ([@bb0090]) reported significantly increased risk between the association of lung cancer and oral cancer with the A allele of *ATM* ([@bb0075; @bb0085; @bb0090]) but the rest of the studies ([@bb0080; @bb0095; @bb0100; @bb0105; @bb0110; @bb0115]) could not find any association between the A allele and cancer risk. In our meta-analysis, it was clear that the variant A allele resulted in cancer risk compared to the G allele. Homozygote, recessive and allele models could not show significant cancer risk with the A allele compared to the G allele. Homozygote dominant vs. Heterozygote (GG vs. GA) model also did not show any risk of cancer having A allele. However, Dominant model (GG vs. GA + AA), heterozygote vs. homozygote mutant (GA vs. AA) model showed significant cancer risk associated with A allele in comparison to the G allele.

It would be interesting to determine the effect of interaction between the *ATM* rs189037 (G \> A) polymorphism and various etiological habits such as smoking, alcohol consumption, betel-quid use etc. on lung cancer and head and neck cancer risk. However, the unavailability of required data in all the studies included in this meat-analysis restricted the evaluation.

5. Conclusion {#s0050}
=============

This study provides for the first time conclusive evidence that *ATM* rs189037 (G \> A) polymorphism is associated with risk of lung cancer and head and neck cancer, which may encourage further large scale population/hospital based case--control/cohort studies.
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###### 

Characteristics of relevant studies included in meta-analysis and genotypic frequencies of rs189037 G \> A.

  Study       Ethnicity    Type of cancer                Source of control   Genotyping method                      Rs189037 G \> A (case/control)   p^a^ value   Case   Control                     
  ----------- ------------ ----------------------------- ------------------- -------------------------------------- -------------------------------- ------------ ------ --------- ----- ----- ----- -----
  [@bb0075]   Asians       Lung                          HB                  TaqMan real-time PCR                   852/852                          0.29         217    435       200   264   434   154
  [@bb9995]   Asians       Papillary thyroid carcinoma   HB                  MALDI-TOF-MS                           355/360                          0.26         90     196       69    102   189   69
  [@bb0085]   Asians       Lung                          HB                  TaqMan real-time PCR                   487/516                          0.12         148    240       99    152   272   92
  [@bb0090]   Asians       Oral                          HB                  PCR-RFLP                               620/620                          0.47         181    277       162   239   285   96
  [@bb9910]   Caucasians   Papillary thyroid carcinoma   PB                  Illumina GoldenGate Genotyping Assay   68/201                           0.31         13     32        23    35    106   60
  [@bb9915]   Asians       Papillary thyroid carcinoma   HB                  TaqMan assay                           428/182                          0.34         134    211       83    56    84    42
  [@bb0105]   Asians       Lung                          HB                  MassARRAY assay                        728/717                          0.72         238    345       145   239   354   124
  [@bb0110]   Asians       Lung                          HB                  SNP-IT assays                          611/614                          0.71         190    316       105   195   306   113
  [@bb0115]   Asians       Lung                          HB                  PCR-RFLP                               358/716                          0.61         118    176       64    255   339   122

p^a^ value \> 0.05 indicates control group is in Hardy--Weinberg equilibrium equation.

###### 

Main result of pooled ORs of ATM rs189037 G \> A polymorphism.

  Genotype rs189037 G \> A   OR     95% CI       p^b^ value   p value for Cochran Q test   I^2^    Combination method
  -------------------------- ------ ------------ ------------ ---------------------------- ------- --------------------
  GG vs. AA                  1.23   1.00--1.51   0.053        0.01                         63.6%   Random effect
  GG vs. (GA + AA)           1.14   1.05--1.25   0.003        0.17                         31.6%   Fixed effect
  (GG + GA) vs. AA           1.17   1.00--1.40   0.068        0.01                         60.7%   Random effect
  G vs. A                    1.11   1.00--1.23   0.046        0.01                         63.7%   Random effect
  GG vs. GA                  1.09   1.00--1.20   0.066        0.66                         0%      Fixed effect
  GA vs. AA                  1.17   1.04--1.30   0.006        0.63                         45.8%   Fixed effect

b --- p heterogeneity.
